Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: Focus on cognition

Biochemical Pharmacology

Volumn 74, Issue 8, 2007, Pages 1212-1223

  Wilens, Timothy E ^a   Decker, Michael W ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

ABT 089; ABT 418; ADHD; Adolescents; Children; Cognitive deficits; Treatment

Indexed keywords

2 METHYL 3 (2 PYRROLIDINYLMETHOXY)PYRIDINE; 3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; DIHYDRO BETA ERYTHROIDINE; ISPRONICLINE; METHYLPHENIDATE; NICOTINE PATCH; NICOTINIC AGENT;

ALZHEIMER DISEASE; ARTICLE; ATTENTION DEFICIT DISORDER; CHOLINERGIC TRANSMISSION; CLINICAL TRIAL; HUMAN; NONHUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA;

ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; COGNITION; HUMANS; ISOXAZOLES; NICOTINIC AGONISTS; PYRIDINES; PYRROLIDINES; RECEPTORS, NICOTINIC; SYNAPTIC TRANSMISSION;

EID: 34548670751     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.07.002     Document Type: Article

References (167)

1. Goldman L., Genel M., Bezman R.J., and Slanetz P.J. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. J Am Med Assoc 279 (1998) 1100-1107
2. Faraone S.V., Sergeant J., Gillberg C., and Biederman J. The worldwide prevalence of ADHD: is it an American condition?. World Psychiatry 2 (2003) 104-113
3. Barkley R.A., Fischer M., Edelbrock C.S., and Smallish L. The adolescent outcome of hyperactive children diagnosed by research criteria. I. An 8-year prospective followup study. J Am Acad Child Adolesc Psychiatry 29 (1990) 546-557
4. Weiss G., Hechtman L., Milroy T., and Perlman T. Psychiatric status of hyperactives as adults: a controlled prospective 15-year follow up of 63 hyperactive children. J Am Acad Child Adolesc Psychiatry 24 (1985) 211-220
5. Weiss G. Attention-deficit disorder. Child and adolescent psychiatric clinics of north America (1992), W.B. Saunders Company, Philadelphia, PA
6. Mannuzza S., Klein R.G., Bessler A., Malloy P., and LaPadula M. Adult outcome of hyperactive boys: Educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry 50 (1993) 565-576
7. Mannuzza S., Klein R.G., Bessler A., Malloy P., and Hynes M. Educational and occupational outcome of hyperactive boys grown up. J Am Acad Child Adolesc Psychiatry 36 (1997) 1222-1227
8. Hechtman L., and Weiss G. Controlled prospective fifteen-year follow-up of hyperactives as adults: non-medical drug and alcohol use and anti-social behaviour. Can J Psychiatry 31 (1986) 557-567
9. Achenbach T.M., Howell C.T., McConaughy S.H., and Stanger C. Six-year predictors of problems in a national sample of children and youth. I. Cross-informant syndromes. J Am Acad Child Adolesc Psychiatry 34 (1995) 336-347
10. Hart E.L., Lahey B.B., Loeber R., Applegate B., and Frick P.J. Developmental change in attention-deficit hyperactivity disorder in boys: a four-year longitudinal study. J Abnorm Child Psychol 23 (1995) 729-749
11. Loney J., Kramer J., and Milich R.S. The hyperactive child grows up: predictors of symptoms, delinquency and achievement at followup. In: Gadow K., and Loney J. (Eds). Psychosocial aspects of drug treatment for hyperactivity (1981), Westview Press, Boulder, CO 381-415
12. Biederman J., Faraone S., Milberger S., Guite J., Mick E., Chen L., et al. A prospective 4-year follow-up study of attention-deficit hyperactivity and related disorders. Arch Gen Psychiatry 53 (1996) 437-446
13. Biederman J., Faraone S.V., Spencer T., Wilens T.E., Norman D., Lapey K.A., et al. Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry 150 (1993) 1792-1798
14. Shekim W.O., Asarnow R.F., Hess E., Zaucha K., and Wheeler N. A clinical and demographic profile of a sample of adults with attention deficit hyperactivity disorder, residual state. Compr Psychiatry 31 (1990) 416-425
15. Biederman J. Attention-deficit/hyperactivity disorder: a life-span perspective. J Clin Psychiatry 59 (1998) 4-16
16. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. (1994), American Psychiatric Association, Washington, DC
17. Denckla M.B. Executive function, the overlap zone between attention deficit hyperactivity disorder and learning disabilities. Int Pediatr 4 (1989) 155-160
18. Barkley R.A. Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. Psychol Bull 121 (1997) 65-94
19. Chelune G.J., Ferguson W., Koon R., and Dickey T.O. Frontal lobe disinhibition in attention deficit disorder. Child Psychiatry Hum Dev 16 (1986) 221-234
20. Clark C., Prior M., and Kinsella G. The relationship between executive function abilities, adaptive behaviour, and academic achievement in children with externalising behaviour problems. J Child Psychol Psychiatry 43 (2002) 785-796
21. Sergeant J. A theory of attention: an information processing perspective. In: Lyon G., and Krasnegor K. (Eds). Attention, memory, and executive function (1996), Paul H. Brooks, Baltimore, MD 57-71
22. Sergeant J., Geurts H., and Oosterlaan J. How specific is a deficit of executive functioning for attention deficit hyperactivity disorder?. Behav Brain Res 130 (2002) 3-28
23. Douglas V.I. Stop, look and listen: the problem of sustained attention and impulse control in hyperactive and normal children. Can J Behav Sci 4 (1972) 259-282
24. Deuel R.K. Minimal brain dysfunction, hyperkinesis, learning disabilities, attention deficit disorder. J Pediatr 98 (1981) 912-915
25. Mattes J. The role of frontal lobe dysfunction in childhood hyperkinesis. Compr Psychiatry 21 (1980) 358-369
26. Lahey B.B., and Carlson C.L. Validity of a diagnostic category of attention deficit disorder without hyperactivity (1989), Committee on Disruptive Behavior Disorders of the Task Force for DSM-IV
27. Lahey BB. Analysis of DSM-IV field trials; 1992.
28. Biederman J., Faraone S., and Mick E. Age dependent decline of ADHD symptoms revisited: Impact of remission definition and symptom subtype. Am J Psychiatry 157 (2000) 816-817
29. Seidman J., Biederman J., Faraone S., Monuteaux M., and Weber W. Neuropsychological findings in ADHD children: findings from a sample of ADHD children (abstract). 44th Annual Meeting of the American Academy of Child & Adolescent Psychiatry. Toronto, October 14-19 (1997)
30. Fischer M., Barkley R.A., Edelbrock C.S., and Smallish L. The adolescent outcome of hyperactive children diagnosed by research criteria. II. Academic, attentional, and neuropsychological status. J Consult Clin Psychol 58 (1990) 580-588
31. Millstein R.B., Wilens T.E., Biederman J., and Spencer T.J. Presenting ADHD symptoms and subtypes in clinically referred adults with ADHD. J Atten Disord 2 (1997) 159-166
32. Murphy P. Cognitive functioning in adults with attention-deficit/hyperactivity disorder. J Atten Disord 5 (2002) 203-209
33. Faraone S.V., Biederman J., Monuteaux M., and Seidman L. Attention deficit hyperactivity disorder and learning disability: a prospective four-year follow-up study. J Atten Disord 3 (2001) 23-25
34. Seidman L.J., Biederman J., Faraone S.V., Weber W., and Ouellette C. Toward defining a neuropsychology of ADHD: performance of children and adolescents from a large clinically referred sample. J Consult Clin Psychol 65 (1997) 150-160
35. Schachar R., Tannock R., Marriott M., and Logan G. Deficient inhibitory control in attention deficit hyperactivity disorder. J Abnorm Child Psychol 23 (1995) 411-437
36. Pennington B.F., and Ozonoff S. Executive functions and developmental psychopathology. J Child Psychol Psychiatry 37 (1996) 51-87
37. Jenkins M., Cohen R., Malloy Pl, Salloway S., Johnson E.G., Penn J., et al. Neuropsychological measures which discriminate among adults with residual symptoms of attention deficit disorder and other attentional complaints. Clin Neuropsychologist 12 (1998) 74-83
38. Welsh M.C., and Pennington B.F. Assessing frontal lobe functioning in children: views from developmental psychology. Dev Neuropsychol 4 (1988) 199-230
39. Barkley R.A. Attention deficit hyperactivity disorder: a handbook for diagnosis and treatment (1990), Guilford Press, New York, NY
40. Bush G., Frazier J.A., Rauch S.L., Seidman L.J., Whalen P.J., Jenike M.A., et al. Anterior cingulate cortex dysfunction in attention-deficit/hyperactivity disorder revealed by fMRI and the counting stroop. Biol Psychiatry 45 (1999) 1542-1552
41. Walker A.J., Shores E.A., Trollor J.N., Lee T., and Sachdev P.S. Neuropsychological functioning of adults with attention deficit hyperactivity disorder. J Clin Exp Neuropsychol 22 (2000) 115-124
42. Carter C.S., Krener P., Chaderjian M., Northcutt C., and Wolfe V. Abnormal processing of irrelevant information in attention deficit hyperactivity disorder. Psychiatry Res 56 (1995) 59-70
43. Seidman L.J., Biederman J., Weber W., Hatch M., and Faraone S. Neuropsychological function in adults with attention-deficit hyperactivity disorder. Biol Psychiatry 44 (1998) 260-268
44. Seidman L.J., Benedict K.B., Biederman J., Bernstein J.H., Seiverd K., Milberger S., et al. Performance of children with ADHD on the Rey-Osterrieth complex figure: a pilot neuropsychological study. J Child Psychol Psychiatry 36 (1995) 1459-1473
45. Seidman L. Neuropsychological testing. In: Tasman A., Kay J., and Lieberman J. (Eds). Psychiatry (1997), W.B. Saunders Company 498-508
46. Brown T.E., and Quinlan D.M. Executive function impairments in high IQ adults with ADHD (1999), Yale University School of Medicine, New Haven, CT
47. Matochik J., Rumsey J., Zametkin A., Hamburger S., and Cohen R. Neuropsychological correlates of familial attention-deficit hyperactivity disorder in adults. Neuropsychiatry Neuropsychol Behav Neurol 9 (1996) 186-191
48. Barkley R.A., and Grodzinsky G.M. Are tests of frontal lobe functions useful in the diagnosis of attention deficit disorders?. Clin Neuropsychologist 8 (1994) 121-139
49. Doyle A., Biederman J., Seidman L., Weber W., and Faraone S. Diagnostic efficiency of neuropsychological test scores for discriminating boys with and without attention deficit hyperactivity disorder. J Consult Clin Psychol 68 (2000) 477-488
50. Goldstein J.M., Seidman L.J., Goodman J.M., Koren D., Lee H., Weintraub S., et al. Are there sex differences in neuropsychological functions among patients with schizophrenia?. Am J Psychiatry 155 (1998) 1358-1364
51. Grodzinsky G., and Diamond R. Frontal lobe functioning in boys with attention deficit hyperactivity disorder. Dev Neuropsychol 8 (1992) 427-445
52. Seidman L.J., Biederman J., Faraone S.V., Milberger S., Norman D., Seiverd K., et al. Effects of family history and comorbidity on the neuropsychological performance of children with ADHD: preliminary findings. J Am Acad Child Adolesc Psychiatry 34 (1995) 1015-1024
53. Biederman J., Petty C., Fried R., Fontanella J., Doyle A.E., Seidman L., et al. Impact of psychometrically-defined executive function deficits in adults with ADHD. Am J Psychiatry 163 (2006) 1730-1738
54. Wilens T., Faraone S.V., and Biederman J. Attention-deficit/hyperactivity disorder in adults. J Am Med Assoc 292 (2004) 619-623
55. Wilens T.E., and Spencer T. The stimulants revisited. In: Stubbe C. (Ed). Child and adolescent psychiatric clinics of north America (2000), Saunders, Philadelphia, PA 573-603
56. Wilens T., Spencer T., and Biederman J. A review of the pharmacotherapy of adults with attention-deficit/hyperactivity disorder. J Atten Disord 5 (2002) 189-202
57. Greenhill L., and Osman B. Ritalin: theory and practice (1999), Mary Ann Liebert, New York, NY
58. Barkley R.A. A review of stimulant drug research with hyperactive children. J Child Psychol Psychiatry 18 (1977) 137-165
59. Swanson J., McBurnett K., Christian D., and Wigal T. Stimulant medications and the treatment of children with ADHD. In: Ollendick T., and Prinz R. (Eds). Adv Clin Child Psychol (1995), Plenum Press, New York, NY 265-322
60. Zametkin A., and Ernst M. Problems in the management of attention-deficit-hyperactivity disorder. N Engl J Med 340 (1999) 40-46
61. Greenhill L.L., Pliszka S., Dulcan M.K., Bernet W., Arnold V., Beitchman J., et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 41 (2002) 26S-49S
62. Simpson D., and Plosker G.L. Spotlight on atomoxetine in adults with attention-deficit hyperactivity disorder. CNS Drugs 18 (2004) 397-401
63. Hah M., and Chang K. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents with bipolar disorders. J Child Adolesc Psychopharmacol 15 (2005) 996-1004
64. Pelham W.E. The effects of psychostimulant drugs on learning and academic achievement in children with attention-deficit disorders and learning disabilities. In: Torgesen J.K., and Wong B. (Eds). Psychological and educational perspectives on learning disabilities (1986), Academic Press, New York, NY 259-295
65. Pelham W.E., Sturges J., Hoza J., Schmidt C., Bijlsma J.J., Milich R., et al. Sustained release and standard methylphenidate effects on cognitive and social behavior in children with attention deficit disorder. Pediatrics 80 (1987) 491-501
66. Gittelman-Klein R. Pharmacotherapy of childhood hyperactivity: an update. In: Meltzer H. (Ed). Psychopharmacology: the third generation of progress (1987), Raven Press, New York, NY 1215-1224
67. Fischer M. Persistence of ADHD into adulthood: it depends on whom you ask. The ADHD report 1997;5:8-10.
68. Spencer T. A controlled, long-term trial of methylphenidate in the treatment of adults with ADHD: preliminary data. Annual meetings of the American Psychiatric Association. Philadelphia, PA (May 2002)
69. Tannock R., Schachar R.J., Carr R.P., Chajczyk D., and Logan G.D. Effects of methylphenidate on inhibitory control in hyperactive children. J Abnorm Child Psychol 17 (1989) 473-491
70. Tannock R., Schachar R.J., Carr R.P., and Logan G.D. Dose-response effects of methylphenidate on academic performance and overt behavior in hyperactive children. Pediatrics 84 (1989) 648-657
71. Tannock R., Ickowicz A., and Schachar R. Differential effects of methylphenidate on working memory in ADHD children with and without comorbid anxiety. J Am Acad Child Adolesc Psychiatry 34 (1995) 886-896
72. Schachar R., Tannock R., Cunningham C., and Corkum P. Behavioral, situational, and temporal effects of treatment of ADHD with methylphenidate. J Am Acad Child Adolesc Psychiatry 36 (1997) 754-763
73. Brown R., and Sawyer M. Short-term cognitive and behavioral effects of psychotropic medications. In: Brown R., and Sawyer M. (Eds). Medications for school-aged kids (1998), Guilford, New York, NY 29-61
74. Rapport M.D., Jones J.T., DuPaul G.J., Kelly K.L., Gardner M.J., Tucker S.B., et al. Attention deficit disorder and methylphenidate: group and single-subject analyses of dose effects on attention in clinic and classroom settings. J Clin Child Psychol 16 (1987) 329-338
75. Rapport M.D., and DuPaul G.J. Hyperactivity and methylphenidate: rate-dependent effects on attention. Int Clin Psychopharmacol 1 (1986) 45-52
76. Douglas V.I., Barr R.G., Desilets J., and Sherman E. Do high doses of stimulants impair flexible thinking in attention-deficit hyperactivity disorder?. J Am Acad Child Adolesc Psychiatry 34 (1995) 877-885
77. Keith R.W., and Engineer P. Effects of methylphenidate on the auditory processing abilities of children with attention deficit-hyperactivity disorder. J Learn Disabil 24 (1991) 630-636
78. Balthazor M.J., Wagner R.K., and Pelham W.E. The specificity of the effects of stimulant medication on classroom learning-related measures of cognitive processing for attention deficit disorder children. J Abnorm Child Psychol 19 (1991) 35-52
79. Kempton s., Vance A., Maruff P., Luk E., Costin J., and Pantelis C. Executive function and ADHD: stimulant medication and better executive function performance in children. Psychol Med 29 (1999) 527-538
80. Riordan H.J., Flashman L.A., Saykin A.J., Fruitger S.A., Carroll K.E., and Huey L. Neuropsychological correlates of methylphenidate treatment in adult ADHD with and without depression. Arch Clin Neuropsychol 14 (1999) 217-233
81. Faraone S.V., Biederman J., Spencer T., Michelson D., Adler L., Reimherr F., et al. Atomoxetine and stroop task performance in adult attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 15 (2005) 664-670
82. Werry J., and Aman M. Methylphenidate and haloperidol in children. Effects on memory and activity. Arch Gen Psychiatry 32 (1975) 790-795
83. Werry J.S. Pediatric psychopharmacology. The use of behavior modifying drugs in children (1978), Brunner/Mazel, New York, NY
84. Wilens T.E., Biederman J., Spencer T.J., Frazier J., Prince J., Bostic J., et al. Controlled trial of high doses of pemoline for adults with attention- deficit/hyperactivity disorder. J Clin Psychopharmacol 19 (1999) 257-264
85. Castellanos F.X., Giedd J.N., Eckburg P., Marsh W.L., Vaituzis A.C., Kaysen D., et al. Quantitative morphology of the caudate nucleus in attention deficit hyperactivity disorder. Am J Psychiatry 151 (1994) 1791-1796
86. Hynd G.W., Hern K.L., Novey E.S., Eliopulis D., Marshall R., Gonzalez J.J., et al. Attention deficit-hyperactivity disorder and asymmetry of the caudate nucleus. J Child Neurol 8 (1993) 339-347
87. Giedd J.N., Castellanos F.X., Casey B.J., Kozuch P., King A.C., Hamburger S.D., et al. Quantitative morphology of the corpus callosum in attention deficit hyperactivity disorder. Am J Psychiatry 151 (1994) 665-669
88. Zametkin A., and Liotta W. The neurobiology of attention-deficit/hyperactivity disorder. J Clin Psychiatry 59 (1998) 17-23
89. Zametkin A.J., Nordahl T.E., Gross M., King A.C., Semple W.E., Rumsey J., et al. Cerebral glucose metabolism in adults with hyperactivity of childhood onset. N Engl J Med 323 (1990) 1361-1366
90. Hynd G.W., Semrud-Clikeman M., Lorys A.R., Novey E.S., and Eliopulos D. Brain morphology in developmental dyslexia and attention deficit disorder/hyperactivity. Arch Neurol 47 (1990) 919-926
91. Faraone S., Doyle A., Mick E., and Biederman J. Meta-analysis of the association between the 7-repeat allele of the dopamine D4 receptor gene and ADHD. Am J Psychiatry 158 (2001) 1052-1057
92. Faraone S.V., and Biederman J. The neurobiology of attention deficit hyperactivity disorder. In: Charney D.S., Nestler E.J., and Bunney B.S. (Eds). Neurobiology of mental illness (1999), Oxford University Press, Inc., New York, NY 788-801
93. Dykman R.A., Ackerman P.T., and Ogelsby D.M. Selective and sustained attention in hyperactive, learning-disabled, and normal boys. J Nerv Ment Dis 167 (1979) 288-297
94. Gorenstein E.E., Mammato C.A., and Sandy J.M. Performance of inattentive-overactive children on selected measures of prefrontal-type function. J Clin Psychol 45 (1989) 619-632
95. Voeller K. The neurological basis of attention deficit hyperactivity disorder. Int Pediatr 5 (1990) 171-176
96. Castellanos F.X., Giedd J.N., Berquin P.C., Walter J.M., Sharp W., Tran T., et al. Quantitative brain magnetic resonance imaging in girls with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 58 (2001) 289-295
97. Potter A.S., Newhouse P.A., and Bucci D.J. Central nicotinic cholinergic systems: a role in the cognitive dysfunction in attention-deficit/hyperactivity disorder?. Behav Brain Res 175 (2006) 201-211
98. Milberger S., Biederman J., Faraone S., Chen L., and Jones J. ADHD is associated with early initiation of cigarette smoking in children and adolescents. J Am Acad Child Adolesc Psychiatry 36 (1997) 37-44
99. Pomerleau O., Downey K., Stelson F., and Pomerleau C. Cigarette smoking in adult patients diagnosed with attention deficit hyperactivity disorder. J Subst Abuse 7 (1995) 373-378
100. Kollins S.H., McClernon F.J., and Fuemmeler B.F. Association between smoking and attention-deficit/hyperactivity disorder symptoms in a population-based sample of young adults. Arch Gen Psychiatry 62 (2005) 1142-1147
101. Milberger S., Biederman J., Faraone S.V., Chen L., and Jones J. Is maternal smoking during pregnancy a risk factor for attention deficit hyperactivity disorder in children?. Am J Psychiatry 153 (1996) 1138-1142
102. Fung Y.K., and Lau Y.S. Effects of prenatal nicotine exposure on rat striatal dopaminergic and nicotinic systems. Pharmacol Biochem Behav 33 (1989) 1-6
103. Johns J.M., Louis T.M., Becker R.F., and Means L.W. Behavioral effects of prenatal exposure to nicotine in guinea pigs. Neurobehav Toxicol Teratol 4 (1982) 365-369
104. Levin E.D., McClernon F.J., and Rezvani A.H. Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology (Berl) 184 (2006) 523-539
105. Parrott A.C., and Winder G. Nicotine chewing gum (2 mg, 4 mg) and cigarette smoking: comparative effects upon vigilance and heart rate. Psychopharmacology 97 (1989) 257-261
106. Wesnes K., and Warburton D. The effects of cigarettes of varying yield on rapid information processing performance. Psychopharmacology 82 (1984) 338-342
107. Bekker E.M., Bocker K.B.E., Van Hunsel F., van den Berg M.C., and Kenemans J.L. Acute effects of nicotine on attention and response inhibition. Pharmacol Biochem Behavior 82 (2005) 539-548
108. Poltavski D.V., and Petros T. Effects of transdermal nicotine on attention in adult non-smokers with and without attentional deficits. Physiol Behav 87 (2006) 614-624
109. Jones G., Sahakian B., Levy R., Warburton D., and Gray J. Effects of acute subcutaneous nicotine on attention, information and short-term memory in Alzheimer's disease. Psychopharmacology 108 (1992) 485-494
110. Wesnes K., and Warburton D.M. Smoking, nicotine, and human performance. Pharmacol Ther 21 (1983) 189-208
111. Meck W., and Church R. Cholinergic modulation of the content of temporal memory. Behav Neurosci 101 (1987) 457-464
112. Peeke S., and Peeke H. Attention, memory, and cigarette smoking. Psychopharmacology 84 (1984) 205-216
113. Conners C.K., Levin E.D., Sparrow E., Hinton S.C., Erhardt D., Meck W.H., et al. Nicotine and attention in adult attention deficit hyperactivity disorder (ADHD). Psychopharmacol Bull 32 (1996) 67-73
114. Potter A.S., and Newhouse P.A. Effects of acute nicotine administration on behavioral inhibition in adolescents with attention-deficit/hyperactivity disorder. Psychopharmacology (Berl) 176 (2004) 182-194
115. Newhouse P., Sunderland T., Tariot P., Blumhardt C., Weingartner H., Mellow A., et al. Intravenous nicotine in Alzheimer's disease: a pilot study. Psychopharmacology 95 (1988) 171-175
116. Harris J.G., Kongs S., Allensworth D., Martin L., Tregellas J., Sullivan B., et al. Effects of nicotine on cognitive deficits in schizophrenia. Neuropsychopharmacology 29 (2004) 1378-1385
117. Smith R.C., Singh A., Infante M., Khandat A., and Kloos A. Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacology 27 (2002) 479-497
118. Levin E., Conners C., Sparrow E., Hinton S., Erhardt D., Meck W., et al. Nicotine effects on adults with attention-deficit/hyperactivity disorder. Psychopharmacology 123 (1996) 55-63
119. Gehricke J.-G., Whalen C.K., Jamner L.D., Wigal T.L., and Steinhoff K. The reinforcing effects of nicotine and stimulant medication in the everyday lives of adult smokers with ADHD: A preliminary examination. Nicotine Tobacco Res 8 (2006) 37-47
120. Decker M.W., and Arneric S.P. Nicotinic acetylcholine receptor-targeted compounds: a summary of the development pipeline and therapeutic potential. In: Arneric S.P., and Brioni J.D. (Eds). Neuronal nicotinic receptors: pharmacology and therapeutic opportunities (1999), Wiley-Liss, New York, NY 395-411
121. Decker M.W., Brioni J.D., Bannon A.W., and Arneric S.P. Diversity of neuronal nicotinic acetylcholine receptors: lessons from behavior and implications for CNS therapeutics. Life Sci 56 (1995) 545-570
122. Decker MW, Sullivan JP, Arneric SP, Williams M. Neuronal nicotinic acetylcholine receptors: novel targets for CNS therapeutics. Psychopharmacology: fourth generation of progress. Chapter update published online on the ACNP Scientific Website at: http://www.acnp.org/citations/GN401000009/;. 2000.
123. Changeux J.P., Bertrand D., Corringer P.J., Dehaene S., Edelstein S., Lena C., et al. Brain nicotinic receptors: structure and regulation, role in learning and reinforcement. Brain Res Brain Res Rev 26 (1998) 198-216
124. Sargent P.B. The diversity of neuronal nicotinic acetylcholine receptors. Ann Rev Neurosci 16 (1993) 403-443
125. Wang N., Orr-Urtreger A., and Korczyn A.D. The role of neuronal nicotinic acetylcholine receptor subunits in autonomic ganglia: lessons from knockout mice. Prog Neurobiol 68 (2002) 341-360
126. Gotti C., and Clementi F. Neuronal nicotinic receptors: from structure to pathology. Prog Neurobiol 74 (2004) 363-396
127. Gotti C., Zoli M., and Clementi F. Brain nicotinic acetylcholine receptors: native subtypes and their relevance. Trend Pharmacol Sci 27 (2006) 482-491
128. Decker M.W., and McGaugh J.L. The role of interactions between the cholinergic system and other neuromodulatory systems in learning and memory. Synapse 7 (1991) 151-168
129. Wonnacott S. Presynaptic nicotinic ACh receptors. Trends Neurosci 20 (1997) 92-98
130. Cummings J.L. Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry 157 (2000) 4-15
131. Sarter M., Hasselmo M.E., Bruno J.P., and Givens B. Unraveling the attentional functions of cortical cholinergic inputs: interactions between signal-driven and cognitive modulation of signal detection. Brain Res Rev 48 (2005) 98-111
132. McGaughy J., Dalley J.W., Morrison C.H., Everitt B.J., and Robbins T.W. Selective behavioral and neurochemical effects of cholinergic lesions produced by intrabasalis infusions of 192 IgG-Saporin on attentional performance in a five-choice serial reaction time task. J. Neurosci. 22 (2002) 1905-1913
133. Westfall T., Grant H., and Perry H. Release of dopamine and 5-hydroxytryptamine from rat striatal slices following activation of nicotinic cholinergic receptors. Gen Pharmacol 14 (1983) 321-325
134. Mereu G., Yoon K., Gessa G., Naes L., and Westfall T. Preferential stimulation of ventral tegmental area dopaminergic neurons by nicotine. Eur J Pharmacol 141 (1987) 395-399
135. Krause K.H., Dresel S.H., Krause J., Kung H.F., Tatsch K., and Ackenheil M. Stimulant-like action of nicotine on striatal dopamine transporter in the brain of adults with attention deficit hyperactivity disorder. Int J Neuropsychopharmacol 5 (2002) 111-113
136. Adams J.P., and Sweatt J.D. Molecular psychology: roles for the ERK MAP kinases cascade in memory. Ann Rev Pharmcol. Toxicol 42 (2002) 135-163
137. Svenningsson P., Nishi A., Fisone G., Girault J.A., Nairn A.C., and Greengard P. DARPP-32: an integrator of neurotransmission. Ann Rev Pharmacol Toxicol 44 (2004) 269-296
138. Pichat P., Bergis O.E., Terranova J.P., Urani A., Duarte C., Santucci V., et al. SSR180711, a novel selective alpha 7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. Neuropsychopharmacology 32 (2007) 17-34
139. Wishka D.G., Walker D.P., Yates K.M., Reitz S.C., Jia S., Myers J.K., et al. Discovery of N-((3R)-1-azabicyclo(2.2.2)oct-3-yl)furo(2,3-c)pyridine-5-carboxamide, an agonist of the alpha 7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: Synthesis and structure-activity relationship. J Med Chem 49 (2006) 4425-4436
140. Tatsumi R., Fujio M., Takanashi S., Numata A., Katayama J., Satoh H., et al. (R)-3′-(3-methylbenzo(b)thiophen-5-yl)spiro(1-azabicyclo(2,2,2)octane-3,5′-oxazolidin)-2′-one, a novel and potent alpha 7 nicotinic acetylcholine receptor partial agonist displays cognitive enhancing properties. J Med Chem 49 (2006) 4374-4383
141. Mazurov A., Hauser T., and Miller C.H. Selective alpha 7 nicotinic acetylcholine receptor ligands. Curr Med Chem 13 (2006) 1567-1584
142. van Kampen M., Selbach K., Schneider R., Schiegel E., Boess F., and Schreiber R. AR-R 17779 improves social recognition in rats by activation of nicotinic alpha(7) receptors. Psychopharmacology 172 (2004) 375-383
143. Curzon P., Anderson D.J., Nikkel A.L., Fox G.B., Gopalakrishnan M., Decker M.W., et al. Antisense knockdown of the rat [alpha]7 nicotinic acetylcholine receptor produces spatial memory impairment. Neurosci Lett 410 (2006) 15-19
144. Hahn B., Sharples C.G.V., Wonnacott S., Shoaib M., and Stolerman I.P. Attentional effects of nicotinic agonists in rats. Neuropharmacology 44 (2003) 1054-1067
145. Curzon P., Brioni J.D., and Decker M.W. Effect of intraventricular injections of dihydro-beta-erythroidine (DHBE) on spatial memory in the rat. Brain Res 714 (1996) 185-191
146. Wehner J.M., Keller J.J., Keller A.B., Picciotto M.R., Paylor R., Booker T.K., et al. Role of neuronal nicotinic receptors in the effects of nicotine and ethanol on contextual fear conditioning. Neuroscience 129 (2004) 11-24
147. Cordero-Erausquin M., Marubio L.M., Klink R., and Changeux J.P. Nicotinic receptor function: new perspectives from knockout mice. Trend Pharmacol Sci 21 (2000) 211-217
148. Granon S., Faure P., and Changeux J.P. Executive and social behaviors under nicotinic receptor regulation. Proc Natl Acad Sci USA 100 (2003) 9596-9601
149. Hahn B., Shoaib M., and Stolerman I.P. Involvement of the prefrontal cortex but not the dorsal hippocampus in the attention-enhancing effects of nicotine in rats. Psychopharmacology 168 (2003) 271-279
150. Blondel A., Sanger D.J., and Moser P.C. Characterisation of the effects of nicotine in the five-choice serial reaction time task in rats: antagonist studies. Psychopharmacology 149 (2000) 293-305
151. Todd R.D., Lobos E.A., Sun L.W., and Neuman R.J. Mutational analysis of the nicotinic acetylcholine receptor alpha 4 subunit gene in attention deficit/hyperactivity disorder: evidence for association of an intronic polymorphism with attention problems. Mol Psychiatry 8 (2003) 103-108
152. Gatto G.J., Bohme G.A., Caldwell W.S., Letchworth S.R., Traina V.M., Obinu M.C., et al. TC-1734: an orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotective and long-lasting cognitive effects. CNS Drug Rev. 10 (2004) 47-66
153. Rueter L.E., Anderson D.J., Briggs C.A., Donnelly-Roberts D.L., Gintant G.A., Gopalakrishnan M., et al. ABT-089: Pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders. CNS Drug Rev 10 (2004) 167-182
154. Arneric S.P., Sullivan J.P., Decker M.W., Brioni J.D., Bannon A.W., Briggs C.A., et al. Potential treatment of Alzheimer disease using cholinergic channel activators (ChCAs) with cognitive enhancement, anxiolytic-like, and cytoprotective properties. Alzheimer Dis Assoc Disord 9 Suppl 2 (1995) 50-61
155. Decker M.W., Bannon A.W., Curzon P., Gunther K.L., Brioni J.D., Holladay M.W., et al. ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride]. II. A novel cholinergic channel modulator with effects on cognitive performance in rats and monkeys. J Pharmacol Exp Ther 283 (1997) 247-258
156. Potter A., Corwin J., Lang J., Piasecki M., Lenox R., and Newhouse P.A. Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease. Psychopharmacology (Berl) 142 (1999) 334-342
157. Wilens T.E., Biederman J., Spencer T.J., Bostic J., Prince J., Monuteaux M.C., et al. A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder. Am J Psychiatry 156 (1999) 1931-1937
158. Wilens T., Verlinden M.H., Adler L.A., Wozniak P.A., and West S.A. ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: results of a pilot study. Biol Psychiatry 59 (2006) 1065-1070
159. Dunbar G.C., Inglis F., Kuchibhatla R., Sharma T., Tomlinson M., and Wamsley J. Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI). J Psychopharmacol 21 (2007) 171-178
160. Arneric S.P., Anderson D.J., Bannon A.W., Briggs C.A., Buccafusco J.J., Brioni J.D., et al. Preclinical pharmacology of ABT-418: a prototypical cholinergic channel activator for the potential treatment of Alzheimer's disease. CNS Drug Rev. 1 (1995) 1-26
161. Sullivan J.P., Donnelly-Roberts D., Briggs C.A., Anderson D.J., Gopalakrishnan M., Xue I.C., et al. ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]. I. A potent and selective cholinergic channel modulator with neuroprotective properties. J Pharmacol Exp Ther 283 (1997) 235-246
162. Man K., Parikh V., Decker M.W., and Sarter M. Differential cholinergic "footprints" evoked by nicotine- and the a4ß2*-selective partial agonist ABT-089 in prefrontal cortex. Neuroscience Meeting Planner (2006), Society for Neuroscience, Atlanta, GA [Program No. 163.7]
163. Brioni J.D., Kim D.J.B., Brodie M.S., Decker M.W., and Arneric S.P. ABT-418: discriminative stimulus properties and effect on ventral tegmental cell activity. Psychopharmacology 119 (1995) 368-375
164. Decker M.W., Bannon A.W., and Curzon P. Septal lesions as model for evaluating potential cognition enhancers. In: Numan R. (Ed). The behavioral neuroscience of the septal region (2000), Springer-Verlag, New York, NY 363-379
165. Prendergast M.A., Jackson W.J., Terry Jr. A.V., Decker M.W., Arneric S.P., and Buccafusco J.J. Central nicotinic receptor agonists ABT-418, ABT-089, and (-)-nicotine reduce distractibility in adult monkeys. Psychopharmacology (Berl) 136 (1998) 50-58
166. Prendergast M.A., Jackson W.J., Terry Jr. A.V., Kille N.J., Arneric S.P., Decker M.W., et al. Age-related differences in distractibility and response to methylphenidate in monkeys. Cereb Cortex 8 (1998) 164-172
167. Arneric S.P., Campbell J.E., Carroll S., Daanen J.F., Holladay M.W., Johnson P., et al. ABT-089 (3-(2(S)-pyrrolidinylmethoxy)-2-methyl-pyridine): an orally effective cholinergic channel modulator with potential once-a-day dosing and cardiovascular safety. Drug Dev Res 41 (1997) 31-43